Eisai Co., Ltd.
Eisai is committed to improving access to medicines in developing and emerging countries, contributing to global health. They focus on human health care (hhc), innovation, and sustainability, aiming to deliver necessary medicines to those in need and advancing medical research and development.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US-8772269-B2
View Details
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US-8772269-B2
View DetailsProducts
Dementia patient information portal (web platform)
Web-based portal providing educational content, caregiver resources, and risk-reduction information related to dementia.
Cancer survivorship digital resource (web platform)
Online resource aimed at supporting female cancer survivors with lifestyle and survivorship information.
Sleep support website (web platform)
Online site providing information and guidance about sleep and insomnia management.
OTC proton pump inhibitor oral tablet (prescription-equivalent dosing)
Over-the-counter oral proton pump inhibitor formulated to contain an active ingredient amount equivalent to the prescription product.
Novel insomnia therapeutic (marketed product, China approval)
New therapeutic for insomnia that has obtained regulatory approval in China.
Dementia patient information portal (web platform)
Web-based portal providing educational content, caregiver resources, and risk-reduction information related to dementia.
Cancer survivorship digital resource (web platform)
Online resource aimed at supporting female cancer survivors with lifestyle and survivorship information.
Sleep support website (web platform)
Online site providing information and guidance about sleep and insomnia management.
OTC proton pump inhibitor oral tablet (prescription-equivalent dosing)
Over-the-counter oral proton pump inhibitor formulated to contain an active ingredient amount equivalent to the prescription product.
Novel insomnia therapeutic (marketed product, China approval)
New therapeutic for insomnia that has obtained regulatory approval in China.
Services
Programmatic supply and distribution of medicines to support public-health campaigns in multiple countries, executed via partnerships with global health stakeholders.
Provision of grants to support medical education initiatives and scientific research dissemination.
Programs and reporting related to medicine access, environmental initiatives, and social responsibility.
Programmatic supply and distribution of medicines to support public-health campaigns in multiple countries, executed via partnerships with global health stakeholders.
Provision of grants to support medical education initiatives and scientific research dissemination.
Programs and reporting related to medicine access, environmental initiatives, and social responsibility.
Expertise Areas
- Neurology and dementia therapeutics
- Oncology drug development
- Sleep disorder therapeutics
- Clinical development and trial management
Key Technologies
- Large-scale oral solid-dose manufacturing
- Web-based patient engagement platforms
- Clinical trial management methodologies
- Regulatory dossier preparation and submission
News & Updates
Eisai announces personnel changes effective July 1, 2025.
Eisai announces personnel changes effective June 20, 2025.
Launch of new OTC proton pump inhibitor drug 'Pariet®S' in Japan.
Victory in patent infringement lawsuit in the US regarding Lenvatinib.
Approval of new sleep disorder drug 'Deevo' in China.
Awarded to researchers who have contributed to the progress and development of natural sciences.
Eisai announces personnel changes effective July 1, 2025.
Eisai announces personnel changes effective June 20, 2025.
Launch of new OTC proton pump inhibitor drug 'Pariet®S' in Japan.
Victory in patent infringement lawsuit in the US regarding Lenvatinib.
Approval of new sleep disorder drug 'Deevo' in China.
Awarded to researchers who have contributed to the progress and development of natural sciences.